From the quarterly update there are two things we should expect an announcement on in August:
Number 1- Regarding COVID ARDS, Mesoblast met with the FDA this week to determine the registration pathway for approval of remestemcel-L in this indication, with formal minutes expected in coming weeks.
IMO Number 2 - Novartis agreement based on the above.
On the 13th of August it will be a year since ODAC voted overwhelmingly for aGVHD To be approved, and we know what the FDA did from there.
The FDA has had some changes in personnel which could bode well for MSB and the science.
August may well be a catalyst for the paradigm shift we’ve all been waiting for, some longer than others and some not at all.
GLTAH
MSB Trading 2021 - paradigm shift, page-6705
-
- There are more pages in this discussion • 3,506 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.02 |
Change
0.005(0.50%) |
Mkt cap ! $1.158B | |||
| Open | High | Low | Value | Volume |
| $1.02 | $1.02 | $1.00 | $1.243M | 1.232M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 33 | 157625 | $1.01 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.02 | 66173 | 13 |
View Market Depth
| Last trade - 14.12pm 19/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |